Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans.

TY - JOUR

T1 - Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans.

AU - Steensberg, Adam

AU - Fischer, Christian P

AU - Sacchetti, Massimo

AU - Keller, Charlotte

AU - Osada, Takuya

AU - Schjerling, Peter

AU - van Hall, Gerrit

AU - Febbraio, Mark A

AU - Pedersen, Bente Klarlund

N1 - Keywords: Adult; Blood Pressure; Energy Metabolism; Epinephrine; Exercise; Glucose; Glucose Transporter Type 4; Glycogen; Heart Rate; Humans; Infusions, Intravenous; Interleukin-6; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Norepinephrine; RNA, Messenger; Recombinant Proteins; Regional Blood Flow

PY - 2003

Y1 - 2003

N2 - The cytokine interleukin (IL)-6 has recently been linked with type 2 diabetes mellitus and has been suggested to affect glucose metabolism. To determine whether acute IL-6 administration affects whole-body glucose kinetics or muscle glucose uptake, 18 healthy young men were assigned to one of three groups receiving a high dose of recombinant human IL-6 (HiIL-6; n = 6), a low dose of IL-6 (LoIL-6; n = 6) or saline (Con; n = 6) infused into one femoral artery for 3 h. The stable isotope [6,6-2H2] glucose was infused into a forearm vein throughout the 3 h infusion period and for a further 3 h after the cessation of infusion (recovery) to determine endogenous glucose production and whole-body glucose disposal. Infusion with HiIL-6 and LoIL-6 resulted in a marked (P < 0.05) increase in systemic IL-6 concentration throughout the 3 h of infusion (mean arterial plasma [IL-6]s of 319 and 143 pg ml-1 for HiIL-6 and LoIL-6, respectively), followed by a rapid decline (P < 0.05) during the recovery period. Subjects experienced clinical symptoms such as shivering and discomfort during HiIL-6 administration, but were asymptomatic during LoIL-6 administration. In addition, only HiIL-6 elevated (P < 0.05) plasma adrenaline (epinephrine). IL-6 infusion, irrespective of dose, did not result in any changes to endogenous glucose production, whole-body glucose disposal or leg- glucose uptake. These data demonstrate that acute IL-6 administration does not impair whole-body glucose disposal, net leg-glucose uptake, or increase endogenous glucose production at rest in healthy young humans.

AB - The cytokine interleukin (IL)-6 has recently been linked with type 2 diabetes mellitus and has been suggested to affect glucose metabolism. To determine whether acute IL-6 administration affects whole-body glucose kinetics or muscle glucose uptake, 18 healthy young men were assigned to one of three groups receiving a high dose of recombinant human IL-6 (HiIL-6; n = 6), a low dose of IL-6 (LoIL-6; n = 6) or saline (Con; n = 6) infused into one femoral artery for 3 h. The stable isotope [6,6-2H2] glucose was infused into a forearm vein throughout the 3 h infusion period and for a further 3 h after the cessation of infusion (recovery) to determine endogenous glucose production and whole-body glucose disposal. Infusion with HiIL-6 and LoIL-6 resulted in a marked (P < 0.05) increase in systemic IL-6 concentration throughout the 3 h of infusion (mean arterial plasma [IL-6]s of 319 and 143 pg ml-1 for HiIL-6 and LoIL-6, respectively), followed by a rapid decline (P < 0.05) during the recovery period. Subjects experienced clinical symptoms such as shivering and discomfort during HiIL-6 administration, but were asymptomatic during LoIL-6 administration. In addition, only HiIL-6 elevated (P < 0.05) plasma adrenaline (epinephrine). IL-6 infusion, irrespective of dose, did not result in any changes to endogenous glucose production, whole-body glucose disposal or leg- glucose uptake. These data demonstrate that acute IL-6 administration does not impair whole-body glucose disposal, net leg-glucose uptake, or increase endogenous glucose production at rest in healthy young humans.

U2 - 10.1113/jphysiol.2002.032938

DO - 10.1113/jphysiol.2002.032938

M3 - Journal article

C2 - 12640021

SN - 0022-3751

VL - 548

SP - 631

EP - 638

JO - The Journal of Physiology

JF - The Journal of Physiology

IS - Pt 2

ER -